Vanda Pharmaceuticals Inc.
VNDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 7% | 5.1% | -5.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 94.7% | 91.5% | 93% | 95.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -52% | -62.5% | -62.2% | -15.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -40.1% | -51.7% | -58.9% | -9.2% |
| EPS Diluted | -0.38 | -0.46 | -0.5 | -0.085 |
| % Growth | 17.4% | 8% | -491.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |